{"title":"Allergen-Specific Human Monoclonal IgG Antibodies for Use in Passive Allergy Immunotherapy.","authors":"Scott A Smith, Cosby A Stone, Alain Jacquet","doi":"10.1111/cea.70153","DOIUrl":"https://doi.org/10.1111/cea.70153","url":null,"abstract":"<p><p>The last decades have shown the number of subjects developing allergic rhinitis (AR), allergic asthma (AA), atopic dermatitis (AD), and food allergy rose continuously worldwide. To cure these allergic diseases, allergen-specific immunotherapy (AIT) represents the unique treatment capable of providing clinical outcomes through the induction of long-term immunological tolerance. Despite proven efficacy, the duration of treatment, AIT-associated side effects, and the difficulty in identifying potential responders by diagnosis lead to poor patient compliance. Clinical investigations evidenced the role of blocking IgG antibodies induced by AIT in long-term tolerance. These observations suggested that passive allergy immunotherapy (PAIT) with low doses of allergen-specific blocking IgG antibodies represents an elegant alternative to frequent administrations of allergen extracts. Tremendous technological progress in the discovery/production of fully human monoclonal antibodies (mAbs) with very low immunogenicity has been made in the last decades, and these therapeutic antibodies revolutionised the treatment of cancers or infectious diseases. The recent advances in the isolation of rare allergen-specific IgE+ B cells and the generation of human antibodies in transgenic mice made possible the production of human monoclonal blocking antibodies against any allergen, sharing the same affinity with the corresponding naturally occurring IgE. This comprehensive review will describe the first promising preclinical and clinical data obtained with antibody cocktails targeting several IgE epitopes to some key single allergens. PAIT is safe and effective for the downregulation of the allergic response. Compared with conventional extract-based AIT, the positive outcomes could require much less dosing.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junhai Chen, Linlu Wang, Xinyue Wang, Yana Zhang, Qintai Yang
{"title":"Treatment Approach to Chronic Rhinosinusitis Based on Endotype: Difference Between East and West.","authors":"Junhai Chen, Linlu Wang, Xinyue Wang, Yana Zhang, Qintai Yang","doi":"10.1111/cea.70150","DOIUrl":"https://doi.org/10.1111/cea.70150","url":null,"abstract":"<p><p>Heterogeneity among CRSwNP patients in Western and Eastern countries leads to differences in management. Type 2 (T2) inflammation accounts for the majority of CRSwNP patients in Western countries, while non-T2 inflammation is the main endotype in CRSwNP patients in Eastern countries. Precise identification of T2 inflammation holds significant promise for optimising treatment outcomes. The treatment of T2 inflammation-biased CRSwNP primarily involves glucocorticoids, reboot surgery, and T2 biologics, while non-T2 inflammation-dominant CRSwNP is mainly treated with macrolide antibiotics.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Usmaan Ahmed, Yitong Shen, Robert L Yellon, Jacqui Galloway, Priya Sellaturay, Shuaib Nasser, Padmalal Gurugama
{"title":"A Safe and Effective 7 Week Updosing Protocol for Bee and Wasp Venom Immunotherapy.","authors":"Usmaan Ahmed, Yitong Shen, Robert L Yellon, Jacqui Galloway, Priya Sellaturay, Shuaib Nasser, Padmalal Gurugama","doi":"10.1111/cea.70149","DOIUrl":"https://doi.org/10.1111/cea.70149","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Innovative Approaches to Allergic Disease Characterisation: Comprehensive Antibody Profiling and Non-Invasive Metabolomics.","authors":"Mohamed H Shamji, Robert J Boyle","doi":"10.1111/cea.70152","DOIUrl":"https://doi.org/10.1111/cea.70152","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinyu Shui, Yu Jiang, Cong Peng, Qiaozhi Cao, Jie Li
{"title":"The Incidence of Addiction and Its Risk Factors in Chinese Chronic Urticaria Patients.","authors":"Xinyu Shui, Yu Jiang, Cong Peng, Qiaozhi Cao, Jie Li","doi":"10.1111/cea.70151","DOIUrl":"https://doi.org/10.1111/cea.70151","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Optimal ImmunoCAP Aspergillus fumigatus-Specific IgE Threshold for Detecting Allergic Bronchopulmonary Aspergillosis in Adults With Asthma: A Diagnostic Accuracy Study.","authors":"Ritesh Agarwal, Puneet Saxena, Valliappan Muthu, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Sahajal Dhooria, Mani Singh, Mandeep Garg, Ashutosh N Aggarwal, Shivaprakash M Rudramurthy, Arunaloke Chakrabarti","doi":"10.1111/cea.70148","DOIUrl":"https://doi.org/10.1111/cea.70148","url":null,"abstract":"<p><strong>Background: </strong>Allergic bronchopulmonary aspergillosis (ABPA) requires screening in adults with asthma using Aspergillus fumigatus-specific IgE (Af-IgE). The current Af-IgE threshold of 0.35 kUA/L has low specificity, leading to unnecessary downstream testing.</p><p><strong>Objectives: </strong>To determine an optimal Af-IgE threshold that maintains high sensitivity while improving specificity for ABPA screening in adults with asthma.</p><p><strong>Methods: </strong>We performed a diagnostic accuracy study of prospectively collected data using distinct derivation and validation cohorts in a tertiary care setting. The index test was ImmunoCAP Af-IgE at thresholds of 0.35, 0.70 and 0.90 kUA/L. The reference standard was the 2024 ISHAM-ABPA criteria applied by investigators aware of all test results.</p><p><strong>Results: </strong>We included 543 consecutive asthmatic subjects investigated for possible ABPA in the derivation cohort (July 2017-September 2018) and 375 subjects with established asthma and ABPA in the validation dataset (January 2020-December 2023). ABPA prevalence was 19.5% (106/543) in derivation and 69.6% (261/375) in validation cohorts. Bayesian latent class analysis estimated a 0.3 kUA/L cut-off but did not improve specificity; frequentist analysis showed model misfit. In the validation cohort, increasing the threshold from 0.35 to 0.70 kUA/L improved specificity from 66.7% (95% CI, 57.6-74.7) to 72.8% (95% CI, 64.0-80.1; p = 0.016) without significant sensitivity reduction (100% to 98.9%; 95% CI, 96.7-99.6; p = 0.25). No patients with bronchiectasis were missed. At 0.90 kUA/L, sensitivity significantly decreased (97.7%; 95% CI, 95.1-98.9; p = 0.031).</p><p><strong>Conclusions: </strong>ImmunoCAP Af-IgE threshold of 0.70 kUA/L optimised diagnostic performance for ABPA screening in adults with asthma, potentially reducing unnecessary confirmatory testing.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicole L Messina, Laure F Pittet, Emily K Forbes, Kaya Gardiner, Katie L Flanagan, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Mike South, Peter Vuillermin, Susan Donath, Dan Casalaz, Nigel Curtis
{"title":"Changes in Atopic Sensitisation From 1 to 5 Years of Age: Longitudinal Data From the MIS BAIR Trial.","authors":"Nicole L Messina, Laure F Pittet, Emily K Forbes, Kaya Gardiner, Katie L Flanagan, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Mike South, Peter Vuillermin, Susan Donath, Dan Casalaz, Nigel Curtis","doi":"10.1111/cea.70144","DOIUrl":"https://doi.org/10.1111/cea.70144","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Viljami E Salmi, Annina Lyly, Mikko Neuvonen, Elmo Saarentaus, Mikko Niemi, Sanna Toppila-Salmi
{"title":"Systemic N-Acylethanolamines and Other Lipid Mediators Are Associated With NSAID-Exacerbated Respiratory Disease.","authors":"Viljami E Salmi, Annina Lyly, Mikko Neuvonen, Elmo Saarentaus, Mikko Niemi, Sanna Toppila-Salmi","doi":"10.1111/cea.70145","DOIUrl":"https://doi.org/10.1111/cea.70145","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}